Viemed Healthcare
VMD
112 hedge funds and large institutions have $233M invested in Viemed Healthcare in 2024 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 35 increasing their positions, 29 reducing their positions, and 13 closing their positions.
62% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 13
27% more capital invested
Capital invested by funds: $184M → $233M (+$49M)
21% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 29
8% more funds holding
Funds holding: 104 → 112 (+8)
2.87% more ownership
Funds ownership: 60.97% → 63.84% (+2.9%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.29M |
| 2 |
KLC
Kent Lake Capital
Reno,
Nevada
|
+$5.05M |
| 3 |
BlackRock
New York
|
+$3.78M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$3.18M |
| 5 |
Goldman Sachs
New York
|
+$3.12M |
Top Sellers
VMD Hedge Fund Activity: Q1 2024 in Review
112 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Viemed Healthcare (VMD) for Q1 2024, worth a combined $233M — up 27% from $184M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new VMD positions and 13 closed out — a net gain of 8 holders — while 35 added to existing stakes and 29 trimmed.
The largest buyer was Vanguard Group, adding an estimated $5.29M. The largest seller was Hillsdale Investment Management, cutting an estimated $3.59M.
- 112 institutional investors held Viemed Healthcare (VMD) as of Q1 2024, up from 104 in Q4 2023.
- Funds reported $233M of Viemed Healthcare stock for Q1 2024, up 27% quarter-over-quarter.
- 21 funds opened new Viemed Healthcare positions in Q1 2024 and 13 closed out, a net change of +8 holders.
- The largest Viemed Healthcare buyer in Q1 2024 was Vanguard Group, an estimated $5.29M added.
- The largest Viemed Healthcare seller in Q1 2024 was Hillsdale Investment Management, an estimated $3.59M sold.
Based on aggregated 13F filings for Q1 2024.